Related Experiment Video

Updated: Jun 17, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with

Toshiyasu Shimomura1, Shinichi Hasako, Yoko Nakatsuru

  • 1Department of Oncology, Banyu Tsukuba Research Institute, Merck Research Laboratories, Tsukuba, Ibaraki, Japan. toshiyasu_shimomura@merck.com

Molecular Cancer Therapeutics
|January 8, 2010
PubMed

Insights

MK-5108 is a novel Aurora-A kinase inhibitor that shows promise in cancer therapy. It effectively inhibits tumor growth and enhances docetaxel efficacy, offering a new therapeutic approach for human cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Aurora-A kinase is a key regulator of mitosis, and its overexpression is linked to human cancers and chromosomal instability.
  • Targeting Aurora-A kinase presents a potential strategy for anticancer therapies.

Purpose of the Study:

  • To evaluate MK-5108, a novel small molecule inhibitor, for its specific activity against Aurora-A kinase.
  • To assess the effects of MK-5108 on cell cycle progression, tumor growth, and its combination efficacy with docetaxel.

Main Methods:

  • In vitro kinase assays to determine specificity.
  • Cell cycle analysis using flow cytometry.
  • Immunostaining assays to detect phosphorylated Histone H3 and Aurora-A autophosphorylation.
  • In vivo studies using nude rat xenograft models.

Main Results:

  • MK-5108 specifically inhibited Aurora-A kinase, unlike other inhibitors targeting both Aurora-A and Aurora-B.
  • MK-5108 induced G(2)-M phase cell cycle arrest and increased phosphorylated Histone H3 in cultured cells and tumor tissues.
  • MK-5108 demonstrated significant inhibition of tumor cell line growth in vitro and in vivo xenograft models.
  • Combination therapy with MK-5108 and docetaxel enhanced antitumor activity without increasing toxicity.

Conclusions:

  • MK-5108 is a potent and specific Aurora-A kinase inhibitor with demonstrated anticancer activity.
  • MK-5108 shows potential as a single agent or in combination with taxane-based therapies for treating human cancers.
  • Further clinical trials are warranted to explore MK-5108's therapeutic potential.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...